静脉白蛋白预防持续低效透析期间血流动力学不稳定的随机对照可行性试验(SAFER-SLED研究)
这项单中心、盲法、安慰剂对照、随机可行性试验纳入60例在ICU启动SLED的急性肾损伤患者,随机接受25%白蛋白或0.9%生理盐水100 mL推注,于SLED开始时和中间各一次,最多10次。10个月入组60例(271次SLED),方案依从性90%,无研究相关不良事件,无失访。白蛋白组所有定义下的血流动力学不稳定均较少,包括收缩压绝对下降均值差10.0 mmHg(95%CI 5.2-14.8),但两组SLED前血管升压药使用存在显著基线差异(白蛋白组80% vs 生理盐水组61%)。超滤量无显著差异。结论认为白蛋白疗效仍不明确,开展更大规模试验可行。
要点
- 单中心盲法安慰剂对照可行性试验,10个月入组60例(271次SLED),方案依从性90%,无研究相关不良事件。
- 白蛋白组和生理盐水组SLED前血管升压药使用分别为80%和61%,存在显著基线差异,解读血流动力学结果需谨慎。
- 白蛋白组所有定义下的血流动力学不稳定均较少,收缩压绝对下降均值差10.0 mmHg(95%CI 5.2-14.8)。
- 超滤量在两组间无显著差异。
- 作者认为超黏稠白蛋白预防SLED期间血流动力学不稳定的疗效仍不明确,开展评估临床相关结局的更大规模试验可行。
适用人群与场景
- 在ICU启动SLED的急性肾损伤患者。
- 多数患者为脓毒症休克,基线需要血管升压药支持。
处置流程与药物剂量
- 25%白蛋白 vs 0.9%生理盐水(对照),每次100 mL推注,于SLED开始时和中间各一次,最多10次。
研究设计与关键结果
- 研究类型:单中心、盲法、安慰剂对照、随机可行性试验;样本量60例(271次SLED);入组时间10个月。
- 干预与对照:25%白蛋白 vs 0.9%生理盐水,100 mL推注,SLED开始时和中间各一次,最多10次。
- 方案依从性244次(90%);无失访;无研究相关不良事件;开放标签白蛋白使用率白蛋白组9% vs 生理盐水组15%。
- 超滤量无显著差异。
- 与生理盐水组相比,白蛋白组所有定义下的血流动力学不稳定均较少,包括收缩压绝对下降均值差10.0 mmHg(95%CI 5.2-14.8);但两组SLED前血管升压药使用存在显著基线差异(白蛋白组80% vs 生理盐水组61%)。
证据类型、等级与局限
- 证据类型:随机对照可行性试验。
- 局限:原文报告两组SLED前血管升压药使用存在显著基线差异(80% vs 61%);作者认为疗效仍不明确。
对床旁实践的改变
- 作者认为超黏稠白蛋白预防危重患者SLED期间血流动力学不稳定的疗效仍不明确,开展评估临床相关结局的更大规模试验可行。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hemodynamic instability is a frequent complication of sustained low-efficiency dialysis (SLED) treatments in the ICU. Intravenous hyperoncotic albumin may prevent hypotension and facilitate ultrafiltration. In this feasibility trial, we sought to determine if a future trial, powered to evaluate clinically relevant outcomes, is feasible.
METHODS: This single-center, blinded, placebo-controlled, randomized feasibility trial included patients with acute kidney injury who started SLED in the ICU. Patients were randomized to receive 25% albumin versus 0.9% saline (control) as 100 mL boluses at the start and midway through SLED, for up to 10 sessions. The recruitment rate and other feasibility outcomes were determined. Secondary exploratory outcomes included ultrafiltration volumes and metrics of hemodynamic instability.
RESULTS: Sixty patients (271 SLED sessions) were recruited over 10 months. Age and severity of illness were similar between study groups. Most had septic shock and required vasopressor support at baseline. Protocol adherence occurred for 244 sessions (90%); no patients were lost to follow-up; no study-related adverse events were observed; open label albumin use was 9% and 15% in the albumin and saline arms, respectively. Ultrafiltration volumes were not significantly different. Compared to the saline group, the albumin group experienced less hemodynamic instability across all definitions assessed including a smaller absolute decrease in systolic blood pressure (mean difference 10.0 mmHg, 95% confidence interval 5.2-14.8); however, there were significant baseline differences in the groups with respect to vasopressor use prior to SLED sessions (80% vs 61% for albumin and saline groups, respectively).
CONCLUSIONS: The efficacy of using hyperoncotic albumin to prevent hemodynamic instability in critically ill patients receiving SLED remains unclear. A larger trial to evaluate its impact in this setting, including evaluating clinically relevant outcomes, is feasible. Trial registration ClinicalTrials.gov (NCT03665311); First Posted: Sept 11th, 2018. https://clinicaltrials.gov/ct2/show/NCT03665311?term=NCT03665311&draw=2&rank=1.
参考来源
- Clark EG, McIntyre L, Watpool I, et al. Intravenous albumin for the prevention of hemodynamic instability during sustained low-efficiency dialysis: a randomized controlled feasibility trial (The SAFER-SLED Study). Ann Intensive Care. 2021. PMID: 34902089. doi:10.1186/s13613-021-00962-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。